Kamada Ltd. (KMDA.TA) Announces New Data on its Glassia Drug Supporting Its Diabetes Activities and Treatment of Additional Therapeutic Indications
11/6/2012 9:57:24 AM
More...
|
Kamada Ltd. (KMDA.TA) and Chiesi Farmaceutici SpA Enter into a Strategic Agreement for Up to $60 Million
8/6/2012 8:07:26 AM
More...
|
Kamada Ltd. (KMDA.TA) Launches a New Website for Its Human Ultrapure Transferrin
11/21/2011 8:58:52 AM
More...
|
Kamada Ltd. (KMDA.TA) Was Granted New Orphan Drug Designation by the FDA for the Treatment of Type 1 Diabetes
8/4/2011 7:10:09 AM
More...
|
Kamada Ltd. (KMDA.TA) Receives an Israeli Patent for its Ultrapure Transferrin for Pharmaceutical Compositions
3/9/2011 10:41:57 AM
More...
|
Kamada Ltd. (KMDA.TA) Announces Successful Interim Report of the Phase 2-3 Clinical Trial with its Inhaled Alpha-1 Antitrypsin
2/14/2011 8:14:27 AM
More...
|
Kamada Ltd. (KMDA.TA) and Baxter International, Inc. (BAX) Enter into a Strategic Agreement for the Distribution and Manufacture of Intravenous Liquid AAT to Treat Alpha-1 Antitrypsin Deficiency in the US; Kamada to Receive Up to $45 Million
8/24/2010 7:02:02 AM
More...
|
Kamada Ltd. (KMDA.TA) Gets FDA Approval For AATD Drug Glassia; Kamada Expects $40 Million Annual Drug Sales
7/6/2010 7:22:36 AM
More...
|
Kamada Ltd. Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
2/8/2010 8:49:45 AM
More...
|
Kamada Ltd. Presents Data on Inhaled Alpha-1 Antitrypsin in Cystic Fibrosis Patients at the European Respiratory Society Meeting 2009, Vienna
9/14/2009 9:23:09 AM
More...
|
|